With current clinical trial results creating “a lot of excitement” in the field of theranostics, Dr. Phillip J. Koo believes FDA approval of this treatment method could offer a potentially curative option for patients with prostate cancer.
Koo, the chief of diagnostic imaging at Banner MD Anderson Cancer Center in Phoenix, recently spoke with CURE® about how patients – some with metastatic disease – are experiencing “amazing” responses with this treatment modality that uses one radioactive drug to identify the cancer and a second to treat it. If cleared for use in this patient population, theranostics offers not just another solid option, but could also pave the way for further trials in other disease states, too.
View more at [ Ссылка ]
CURE: Combining science and humanity to make cancer understandable.
